The frequency of PI3K/Akt pathway malfunctioning has been observed in over 90% and 80% of human CRC and AOM/DSS model, respectively, indicating it to be an important therapeutic target [37,38]. This evidence concerns the gene AKT1 and colorectal carcinoma.